Ampliqon A/S and Methyldetect ApS inked a collaboration agreement

5thof February 2019 Aarhus-Odense, Denmark   MethylDetect ApS, an Aarhus based company established in 2017, to commercialize their proprietary methylation biomarker detection technology invented at Aarhus University. Compared to other available assays the technology is specific, sensitive, rapid, cost effective and run on standard PCR equipment.   Ampliqon A/S is a well-established biotech company located…

Our assay helps to identify cancer predisposition – Lynch Syndrome

MethylDetect’s assay targetting MLH1 gene is now a part of the NICE-mandated Lynch Syndrome pre-screen test. The results showing the performance of our MLH1 methylation testing assays, performed in collaboration with Sarah Cannon Molecular Diagnostics, https://sarahcannon-md.co.uk , were presented at the National Cancer Research Institute conference 2018. see: MLH1 Promoter Hypermethylation: Development and Preliminary Validation of a Methylation-Specific High…